Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Peritoneal adenomatoid (microcystic) mesothelioma.
Mori D, Kido S, Hiraki M, Sumi K, Ureshino N, Masuda M, Nabeshima K, Akashi M. Mori D, et al. Among authors: ureshino n. Pathol Int. 2020 Nov;70(11):876-880. doi: 10.1111/pin.13006. Epub 2020 Sep 3. Pathol Int. 2020. PMID: 32881200
A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
Otsuka T, Shirakawa T, Shimokawa M, Koga F, Kawaguchi Y, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Mitsugi K, Ureshino N. Otsuka T, et al. Among authors: ureshino n. Int J Clin Oncol. 2021 May;26(5):941-950. doi: 10.1007/s10147-021-01859-2. Epub 2021 Jan 23. Int J Clin Oncol. 2021. PMID: 33483857
Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
Otsuka T, Shirakawa T, Shimokawa M, Koga F, Kawaguchi Y, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Mitsugi K, Ureshino N. Otsuka T, et al. Among authors: ureshino n. Int J Clin Oncol. 2021 May;26(5):951-953. doi: 10.1007/s10147-021-01880-5. Int J Clin Oncol. 2021. PMID: 33656656 No abstract available.
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.
Komori A, Otsu S, Shimokawa M, Otsuka T, Koga F, Ueda Y, Nakazawa J, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Shirakawa T, Mitsugi K. Komori A, et al. Among authors: ureshino n. Int J Clin Oncol. 2023 Aug;28(8):1073-1081. doi: 10.1007/s10147-023-02354-6. Epub 2023 May 20. Int J Clin Oncol. 2023. PMID: 37209158
A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401).
Samura H, Oki E, Okumura H, Yoshida T, Kai S, Kobayashi K, Kinjo T, Mori S, Tohyama T, Ohgaki K, Kawanaka H, Makiyama A, Ureshino N, Kotaka M, Shimose T, Ando K, Saeki H, Baba H, Maehara Y, Mori M. Samura H, et al. Among authors: ureshino n. Cancer Chemother Pharmacol. 2020 Aug;86(2):285-294. doi: 10.1007/s00280-020-04108-x. Epub 2020 Jul 30. Cancer Chemother Pharmacol. 2020. PMID: 32734398 Clinical Trial.
21 results